BiotechTube
Axovia Therapeutics

Axovia Therapeutics

Cambridge, United Kingdom· Est.
axoviatherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Axovia Therapeutics is a private, preclinical-stage biotech founded by leading ciliopathy experts to address the significant unmet need in disorders like Bardet-Biedl Syndrome. The company is developing an AAV9-based gene therapy targeting the BBS1 gene mutation, which accounts for approximately 40% of BBS cases, with the dual aims of preventing retinal degeneration and reversing obesity. Operating from the Cambridge biotech hub, Axovia is positioned to leverage advanced genetic medicine platforms to create first-in-class therapies for these rare diseases with no approved treatments.

Rare Genetic DisordersCiliopathiesMetabolic DisordersOphthalmology

Technology Platform

AAV9-based gene therapy platform for delivering functional gene copies to treat monogenic ciliopathies.

Opportunities

The primary opportunity is to develop the first disease-modifying therapy for Bardet-Biedl Syndrome, addressing severe unmet needs in blindness and obesity.
Orphan drug designations could provide regulatory and commercial advantages.
Success in BBS1 could enable platform expansion to other genetic forms of BBS or related ciliopathies.

Risk Factors

Key risks include preclinical-to-clinical translation failure, safety concerns associated with AAV gene therapy (e.g., immunogenicity), and the challenges of developing and commercializing a high-cost therapy for an ultra-rare patient population.
The company's fate is currently tied to a single, early-stage asset.

Competitive Landscape

The competitive landscape for BBS is sparse, with no approved disease-modifying therapies. Competition may emerge from other gene therapy approaches, RNA-targeting therapies, or small molecules in research stages. Axovia's first-mover advantage and focus on the prevalent BBS1 mutation could provide a competitive edge if development is successful.

More companies in Cell & Gene Therapy →More companies in United Kingdom →